China NMPA Inspection - Beijing Tianhe Kangxing Technology Co., Ltd. - April 07, 2016

A surprise inspection report, published on April 7, 2016, by the National Medical Products Administration (NMPA), detailed findings concerning Beijing Tianhe Kangxing Technology Co., Ltd. The company had previously applied for a production suspension on April 28, 2015, due to an expiring factory lease and was actively seeking a new production address. During an unannounced on-site verification, the inspection team confirmed that the company was no longer operating at its original production site, validating the reported suspension. The primary finding was not a direct violation, but rather the essential procedural steps required for future operational compliance. Under the regulatory framework overseen by the NMPA and the Beijing Municipal Food and Drug Administration, Beijing Tianhe Kangxing Technology Co., Ltd. is mandated to submit a written report to the Beijing Municipal Food and Drug Administration before resuming production. Manufacturing activities can only recommence after the local regulatory authority has thoroughly verified that all relevant requirements for a new or re-established production facility are fully met, ensuring adherence to quality and safety standards upon relocation and restart.